Abstract Despite the availability of newer classes of antibiotics, infection with multi-drug-resistant bacteria is a serious problem. To suppress the appearance of multi-drug-resistant bacteria and to avoid severe infection derived from febrile neutropenia (FN), we conducted cycling the administration of antibiotics for FN in patients with hematological malignancy. The treatment protocol consisted of the administration of four antibiotics each for 3 months in 1 year. The above regimen was repeated for 4 years. A total of 193 patients were registered in the protocol. The mean duration of the administration of cycling antibiotics was 5.9 days (range: 1-16 days). The frequency of FN before the study and during the study was unchanged until the third year, but decreased significantly in the fourth year. The frequency of detection of multi-drug-resistant bacteria in the first year was the same as that before the study was started, but dramatically decreased after the second year. Bacteriological treatment success rates were similar in each trimester and each year. The effective rate was not statistically different in each trimester and each year. We conclude that cycling the administration of antibiotics in patients with FN is useful for suppressing the appearance of multi-drug-resistant bacteria and for obtaining excellent clinical efficacy.
Introduction
Febrile neutropenia (FN) is commonly observed in patients with hematological malignancy during chemotherapy and after hematopoietic stem cell transplantation (HSCT), and is usually rapidly progressive [1] . FN must, therefore, be treated urgently as an infection until obtaining the final results of culture. Indeed, Bodey et al. reported that the later the treatment was started in cases of Pseudomonas infection, the lower the rate of treatment success was expected to be [2] . Guidelines for the treatment of FN were proposed by Hughes et al. in 1997 and by Masaoka in 1998 [3, 4] . Thereafter, many antibiotics were reported to have a treatment success rate of 40 to 50% in FN cases with hematological malignancy [5] . Guidelines for the treatment of FN were revised by Hughes et al. in 2002 and by Tamura et al. in 2004 [6, 7] . They recommended that patients with FN be divided into two groups (low-risk and high-risk groups) and treated according to the risk.
Increased quantity of administered antibiotics is usually related to the appearance of and increase in antibioticresistant bacteria. To avoid the concentrated prescription of a few antibiotics in a single institution, cycling or rotated administration of antibiotics has been recommended and performed [8] . However, there are several problems to be solved: (1) the basic scientific theory has not been confirmed; (2) the appropriate choice of drugs, combination, and period of administration have not been established; and (3) clinical studies based on a strict protocol have not been performed. Although Raymond et al. reported that more than 3 months duration of administration resulted in increased incidence of infection [9] , there are no clinical data available for patients with FN.
The prophylactic administration of oral quinolones in patients with hematological diseases receiving chemotherapy and HSCT is commonly performed [10] [11] [12] . The wide use of quinolones in patients with neutropenia is related to a decrease in Gram-negative bacterial infection and increased incidence of Gram-positive bacterial infection [13] [14] [15] . In patients with FN, after autologous peripheral blood stem cell transplantation, intravenous piperacillin-tazobactam (PIPC/ TAZ) as the prophylaxis for FN has been reported to be more effective than fluoroquinolone [16] . Meta-analysis of the results of 35 studies on the treatment of FN showed that cefepime (CFPM), carbapenems, cefoperazone-sulbactam (CPZ/SBT), and PIPC/TAZ were equally effective [17] . Although it was also shown in that study that patients treated with CFPM are at a higher risk for fatal outcome than patients given other beta-lactams, CFPM is widely used for FN in Japan and has been approved as the treatment for FN by the Japanese Ministry of Health, Labour and Welfare. Moreover, drugs for cycling should be theoretically chosen on the basis of different mechanisms of action and different target organs of side effects. All selected antibiotics should also have an anti-Pseudomonas effect. Therefore, we conducted cycling the administration of antibiotics for patients with FN who received prophylactic quinolones during chemotherapy and HSCT using CFPM, panipenembetamipron (PAPM/BP), CPZ/SBT, and PIPC/TAZ.
Materials and methods

Study design
This was a prospective open study conducted in a single institution. The major objective of this study was to evaluate the efficacy and feasibility of cycling antibiotics for FN in patients with hematological malignancy. The primary objective was inhibition of the appearance of multi-drug-resistant bacteria and global resistance against the antibiotics used in the study. The secondary objective was comparison of the efficacy of the different antibiotics for FN. FN is defined as body temperature of more than 38.0°C for more than 1 h, neutrophil count of less than 1,000/μL with a tendency to decrease to less than 500/μL within 24 to 48 h or being less than 500/μL, and no basic disease to induce fever [6, 18, 19] . After obtaining written informed consent, patients were treated according to the protocol. The protocol was reviewed and approved by the Institutional Review Board. The data obtained from this study were compared annually.
Treatment protocol
We conducted cycling the administration of antibiotics for patients with FN who received prophylactic quinolones during chemotherapy and HSCT using CFPM (1 g×2/day), PAPM/BP (1 g×2/day), CPZ/SBT (2 g×2/day), and PIPC/ TAZ (2.5 g×2/day) ( Table 1) . These dosages were decided by the Japanese health insurance systems. The treatment protocol consisted of the administration of four antibiotics with different anti-microbial mechanisms, each for 3 months in 1 year. This regimen was repeated for 4 years. Since we conducted this study over fixed durations (3 months for each drug), we did not calculate the number of subjects required to verify the goals of this study.
Patients
Adult FN patients with hematological malignancy were eligible for the study if they did not have significant hepatic or renal dysfunctions (defined as a level of bilirubin, alanine aminotransferase [ALT], aspartate aminotransferase [AST], or creatinine that was less than two times the upper limit of the normal range). Dosages were not adjusted in patients whose level of bilirubin, ALT, AST, or creatinine was less than two times the upper limit of the normal range. The patients included in this study were only patients with fever of unknown origin. Patients for whom the possibility of non-infectious fever could not be ruled out were included in this study, and patients who suffered from tumor-induced fever were excluded. Patients having a bacterial focus were also excluded from this study. Patients were excluded if they had a previous history of allergy to the antibiotics of this protocol.
Clinical and laboratory evaluations
Multi-drug-resistant bacteria are defined as oxacillin-resistant Staphylococcus aureus or penicillin-resistant Streptococcus pneumoniae and aminoglycoside-, cephem-, and carbapenem-resistant Gram-negative rods. Global resistance here means resistance to the specific antibiotics cycled. In cases in which possible causal bacteria were detected by surveillance culture, bacteriological evaluation of treatment is defined as the disappearance of possible causal bacteria, decrease of the bacteria, unchanged results, change of the bacteria, and unknown [20] . Disappearance and decrease are defined as bacteriological treatment success. The secondary objective was treatment success, defined as temperature being normal for at least three consecutive days without any modifications in the assigned regimen and without evidence of active infection at the time of resolution of neutropenia [19] .
Adverse events were graded on the basis of the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 2.0. Statistical differences were analyzed using Fisher's exact test. Table 2) . Twenty-three patients (12%) received autologous HSCT and 62 patients (32%) received allogeneic HSCT. The median age of the patients was 51.5 years (range: 15-79 years), and 99 (51%) of the patients were males. The underlying diseases of the patients were non-Hodgkin's lymphoma in 69 patients, acute myelogenous leukemia in 41, multiple myeloma in 16, myelodysplastic syndrome in 15, acute lymphoblastic leukemia in 13, chronic myelogenous leukemia in eight, adult T-cell leukemia in six, Hodgkin's lymphoma in three, and other hematological diseases in 22. Oral or intravenous administration of antibiotics was carried out in 81 patients (42%), and 69 patients (36%) received an antibiotic for the decontamination of gastrointestinal tracts. Although granulocyte colonystimulating factor (G-CSF) was used in 165 patients (85%) and macrophage colony-stimulating factor (M-CSF) was used in one patient (1%), 27 patients (14%) did not receive any hematopoietic cytokines. The mean duration of the administration of cycling antibiotics was 5.9 days (range: 1-16 days). The frequency of FN before the study and during the study was unchanged until the third year, but decreased significantly in the fourth year (Table 3) . Clinical treatment success of cycling antibiotics in each period was statistically similar, even during different years (Table 4 ). There was no statistical difference between the four different antibiotics and also between different years. Although the rate of neutrophil count over 500/μl at the end of the study was slightly lower in the last year, clinical efficacy still remained high. The frequency of detection of multi-drugresistant bacteria in colonization in the first year was the same as that before the study was started, but it decreased from the second year and was low in the third and fourth years ( Table 5 ). The appearance of bacteria with resistance against each antibiotic used in the study did not increase compared with that before the study and remained at a low level throughout the study period. Bacteriological treatment success rates were statistically similar in the four years. There were no remarkable changes in the frequency and Multi-drug-resistant bacteria: MRSA and multi-drug-resistant Gram-negativerods showed resistance against cefazolin, cefotiam, cefmetazole, cefotaxime,ceftazidime, cefozopran, cefepime, levofloxacin, ofloxacin, gentamicin andamikacin etiology of fungal infections during the study. Although side effects were observed in 2 to 10% of patients for every drug, grade 3 or 4 adverse effects were never observed.
Results
A total of
193 patients diagnosed as having FN were enrolled in this protocol during the period from May 2003 to April 2007 (
Discussion
One of the most important purposes of cycling therapy is suppression of the appearance of antibiotic-resistant bacteria.
In hematology, the effect of cycling therapy is easily demonstrated because of the relatively long-term administration period and frequent usage of antibiotics. This study showed that the cycling of antibiotics was effective for suppressing the appearance of multi-drug-resistant bacteria from the second year and that the effect was maintained for at least three years thereafter. The effective rates of cycling antibiotics were similar in the trimesters and in the four years. The effective rates in the present study were better than we had expected, even though the subjects included 32% profound immunosuppressive patients after allogeneic HSCT. Bow et al. reported that CFPM and PIPC/TAZ were equally effective for treating patients with FN, about half of whom had received HSCT, and our results are compatible with their results [21] . Our results also showed that the cycling protocol did not have an adverse impact on antimicrobial susceptibility compared with that before the study was started, at least in the first four years after implementation. Although quinolones are not recommended for the treatment of FN because of their already wide use for prophylaxis and although we did not use quinolones in this protocol, Winston et al. recently reported that quinolones have an effect similar to that of carbapenems in FN [22] . Therefore, cycling using quinolones should be performed in cases without the administration of prophylactic quinolones. In this study, some patients received an antibiotic for prophylaxis or decontamination of gastrointestinal tracts and others did not. Therefore, as discussed in previous reports, more studies using similar prophylactic antibiotics should be performed in order to determine what kinds of antibiotics are necessary, how long one treatment period should be, and for how long cycling of the protocol should be repeated.
The degree and duration of neutropenia are among the most important factors influencing the effects of antibiotics. Tamura et al. reported that the success rate of antibiotics in patients with FN who received the drugs when the neutrophil count was less than 500/μL was worse than that in patients who were started on antibiotics when the neutrophil count was between 500 and 1,000/μL [7] . Although the rate of neutrophil count over 500/μL at the end of the study in the fourth year was significantly lower than the rates in the previous years, clinical efficacy in the fourth year was still high and similar to that in the other years. Therefore, the decrease in multi-drug-resistant bacteria after the second year might be related to maintenance of the clinical efficacy of cycling antibiotics at a high level, even in patients with profound neutropenia. The fact that 85% of the patients in this study had received G-CSF might have reduced the negative impact of profound neutropenia.
Bacteriological treatment success was similar in the four years. Decrease in multi-drug-resistant bacteria was not directly related to bacteriological treatment success. Hereafter, the timely and efficient administration of prophylactic antibiotics may be important. Monitoring the bacterial ecology of the units is also important for infectious control. Whether the decrease in frequency of FN in the fourth year was due to the cycling protocol used in this study should be confirmed by using another protocol with a longer treatment period.
In summary, our study clearly showed a beneficial effect of the maintenance of cycling antibiotics in FN patients with hematological malignancy. Since there have been few studies providing data which show that a reduction in the appearance of antibiotic-resistant bacteria improves clinical outcomes and overall survival, further randomized multi-institutional studies with larger numbers of patients should be performed in order to determine the appropriate schedule of cycling antibiotics.
